| Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial WTA Van Der Graaf, JY Blay, SP Chawla, DW Kim, B Bui-Nguyen, ... The Lancet 379 (9829), 1879-1886, 2012 | 2318 | 2012 |
| Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial J Verweij, PG Casali, J Zalcberg, A LeCesne, P Reichardt, JY Blay, ... The Lancet 364 (9440), 1127-1134, 2004 | 2152 | 2004 |
| Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations DM Hyman, I Puzanov, V Subbiah, JE Faris, I Chau, JY Blay, J Wolf, ... New England Journal of Medicine 373 (8), 726-736, 2015 | 1996 | 2015 |
| Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised … GD Demetri, P Reichardt, YK Kang, JY Blay, P Rutkowski, H Gelderblom, ... The Lancet 381 (9863), 295-302, 2013 | 1595 | 2013 |
| Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy CH Ries, MA Cannarile, S Hoves, J Benz, K Wartha, V Runza, ... Cancer cell 25 (6), 846-859, 2014 | 1427 | 2014 |
| CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner F Ghiringhelli, C Ménard, M Terme, C Flament, J Taieb, N Chaput, ... The Journal of experimental medicine 202 (8), 1075-1085, 2005 | 1236 | 2005 |
| NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)—update of the NCCN clinical practice guidelines GD Demetri, RS Benjamin, CD Blanke, JY Blay, P Casali, H Choi, ... Journal of the National Comprehensive Cancer Network 5 (S2), S-1-S-29, 2007 | 1143 | 2007 |
| KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours M Debiec-Rychter, R Sciot, A Le Cesne, M Schlemmer, P Hohenberger, ... European journal of cancer 42 (8), 1093-1103, 2006 | 1108 | 2006 |
| Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial I Judson, J Verweij, H Gelderblom, JT Hartmann, P Schöffski, JY Blay, ... The lancet oncology 15 (4), 415-423, 2014 | 1090 | 2014 |
| Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO JY Blay, S Bonvalot, P Casali, H Choi, M Debiec-Richter, AP Dei Tos, ... Annals of Oncology 16 (4), 566-578, 2005 | 1034 | 2005 |
| Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, N Abecassis, S Bauer, R Biagini, S Bielack, S Bonvalot, ... Annals of Oncology 29, iv51-iv67, 2018 | 1029 | 2018 |
| Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, N Abecassis, S Bauer, R Biagini, S Bielack, S Bonvalot, ... Annals of oncology 29, iv68-iv78, 2018 | 999* | 2018 |
| Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience AJM Ferreri, JY Blay, M Reni, F Pasini, M Spina, A Ambrosetti, ... Journal of Clinical Oncology 21 (2), 266-272, 2003 | 961 | 2003 |
| Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome M Gobert, I Treilleux, N Bendriss-Vermare, T Bachelot, S Goddard-Leon, ... Cancer research 69 (5), 2000-2009, 2009 | 912 | 2009 |
| Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas I Ray-Coquard, C Cropet, M Van Glabbeke, C Sebban, A Le Cesne, ... Cancer research 69 (13), 5383-5391, 2009 | 842 | 2009 |
| Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial P Schöffski, S Chawla, RG Maki, A Italiano, H Gelderblom, E Choy, ... The Lancet 387 (10028), 1629-1637, 2016 | 830 | 2016 |
| Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study RD Issels, LH Lindner, J Verweij, P Wust, P Reichardt, BC Schem, ... The lancet oncology 11 (6), 561-570, 2010 | 801 | 2010 |
| Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for … S Sleijfer, I Ray-Coquard, Z Papai, A Le Cesne, M Scurr, P Schöffski, ... Journal of clinical oncology 27 (19), 3126-3132, 2009 | 797 | 2009 |
| Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study D Thomas, R Henshaw, K Skubitz, S Chawla, A Staddon, JY Blay, ... The lancet oncology 11 (3), 275-280, 2010 | 792 | 2010 |
| Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up ESMO/European Sarcoma Network Working Group Annals of Oncology 25, iii102-iii112, 2014 | 757* | 2014 |
Isabelle Ray-CoquardCentre Leon Berard & Universite Claude Bernard Lyon IEmail được xác minh tại lyon.unicancer.fr